Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly Loses UK High Court Alimta Battle

This article was originally published in Scrip

Executive Summary

Eli Lilly & Co. will continue to "vigorously defend" its Alimta (pemetrexed disodium) patents in the UK, France, Italy and Spain, it said, following a UK High Court ruling last week that will allow competitor Actavis to market a generic version of the cancer drug.


Related Content

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly Executes Growth Strategy As New Products Drive Sales Gains